NVCT Nuvectis Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1875558 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-98.8%
TTM EPS YoY-46.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-67.0%
ROA-57.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio9.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $27.37M | $4.68M | $4.11M | $5.09M | $5.77M | $3.61M | $3.68M | $4.50M |
| SG&A expense | $3.68M | $2.51M | $2.15M | $2.53M | $2.02M | $2.98M | $1.89M | $1.95M |
| Operating income | -$31.05M | -$7.20M | -$6.26M | -$7.62M | -$7.79M | -$6.59M | -$5.57M | -$6.45M |
| Net income | -$30.07M | -$7.02M | -$6.05M | -$7.31M | -$7.46M | -$6.33M | -$5.33M | -$6.25M |
| EPS (basic) | -1.02 | -0.30 | -0.26 | — | -0.44 | -0.30 | -0.27 | — |
| EPS (diluted) | -1.02 | -0.30 | -0.26 | — | -0.44 | -0.30 | -0.27 | — |
| Weighted avg. shares (diluted) | 29.47M | 23.48M | 23.41M | — | 22.72M | 21.37M | 19.94M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $140.71M | $22.16M | $25.13M | $31.63M | $35.44M | $26.79M | $29.86M | $18.53M |
| Current assets | $140.84M | $22.38M | $25.40M | $31.71M | $35.59M | $27.01M | $30.15M | $18.61M |
| Total assets | $140.84M | $22.38M | $25.40M | $31.71M | $35.59M | $27.01M | $30.15M | $18.61M |
| Current liabilities | $14.19M | $13.29M | $11.18M | $13.30M | $11.58M | $10.13M | $9.19M | $8.89M |
| Total liabilities | $14.19M | $13.29M | $11.18M | $13.30M | $11.58M | $10.13M | $9.19M | $8.89M |
| Shareholders' equity | $126.65M | $9.08M | $14.22M | $18.41M | $24.01M | $16.87M | $20.95M | $9.71M |
| Shares outstanding | 34.39M | 26.69M | 26.53M | 25.68M | 25.64M | 23.88M | 23.63M | 19.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25.28M | -$4.53M | -$6.51M | -$3.97M | -$4.49M | -$3.37M | -$4.17M | -$2.46M |
| Investing cash flow | — | — | $0 | — | — | — | $0 | — |
| Financing cash flow | $143.82M | $1.56M | $7,000 | $166,000 | $13.14M | $296,000 | $15.51M | $3.83M |
| Stock-based compensation | $2.42M | $1.71M | $1.85M | $1.48M | $1.46M | $1.73M | $1.37M | $1.14M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.